Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price traded up 31% during mid-day trading on Thursday . The company traded as high as C$0.23 and last traded at C$0.19. 480,687 shares were traded during trading, a decline of 9% from the average session volume of 525,664 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company’s fifty day simple moving average is C$0.20 and its two-hundred day simple moving average is C$0.12. The stock has a market cap of C$27.69 million, a price-to-earnings ratio of -5.54 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- The 3 Best Fintech Stocks to Buy Now
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- What Are Dividend Champions? How to Invest in the Champions
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- The Basics of Support and Resistance
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
